ABSI
NasdaqABSCI CORP
Industrials · Services-Commercial Physical & Biological Research
Research view
Fundamentals · SEC EDGAR · FY 2025-12-31
Revenue & Earnings — fiscal year
$4.0M
2021
$4.5M
2022
$5.7M
2023
$4.5M
2024
$2.8M
2025
Snapshot
SEC EDGAR · FY 2025-12-31Revenue$2.8M
Net Income$-115.2M
Gross Profit—
Oper Income$-120.3M
EPS (dil)$-0.84
Rev/sh$0.02
FCF/sh$-0.60
Book/sh$1.22
Gross M—
Oper M-4297.0%
Profit M-4113.7%
FCF M-3358.3%
ROE-60.8%
ROA-53.3%
ROIC-69.9%
R&D/Rev2907.8%
Rev Y/Y-38.2%
Rev 3Y CAGR-14.8%
EPS Y/Y10.6%
EPS 3Y CAGR—
FCF 3Y CAGR—
Payout—
Div/sh—
Shs Chg Y/Y+24.1%
Current Ratio6.57
Quick Ratio—
Debt/Eq0.02
Int Coverage-575.7×
Net Debt$17.1M cash
Total Debt$4.0M
Cash & Eq$21.1M
Total Assets$216.3M
Oper CF$-92.9M
Capex$1.1M
Free CF$-94.0M
Buybacks—
Equity$189.4M
Liabilities$26.8M
Shs Outstand0.16B
SectorIndustrials
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $4.0M | $4.5M | $5.7M | $4.5M | $2.8M |
| Gross Profit | — | — | — | — | — |
| Operating Income | $-75.2M | $-106.8M | $-115.5M | $-108.9M | $-120.3M |
| Net Income | $-101.0M | $-104.9M | $-110.6M | $-103.1M | $-115.2M |
| Diluted EPS | $-2.08 | $-1.15 | $-1.20 | $-0.94 | $-0.84 |
| Operating Cash Flow | $-60.6M | $-81.3M | $-64.6M | $-72.4M | $-92.9M |
| Free Cash Flow | $-98.6M | $-97.5M | $-65.5M | $-72.8M | $-94.0M |
COMMUNITY · $ABSI0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.